Combination safety cannot be inferred from the idea that two substances should “balance” each other. It depends on the exact medicines, the person’s health and evidence about the combination itself. A plausible mechanism is not a substitute for that evidence.
The 2015 Selank add-on study compared phenazepam alone with phenazepam plus Selank in people with anxiety-related diagnoses. Its abstract reports favorable clinical and tolerability findings for the combined approach. That is evidence about one studied comparison, not a comprehensive interaction assessment covering antidepressants, stimulants, baclofen or multiple simultaneous medicines.
An additional Selank–diazepam stress-model experiment was conducted in rats. It can inform a mechanistic research question, but it cannot supply a safe human combination or a strategy for reducing a prescribed medicine. Translating its behavioral results into a home regimen would require assumptions about species, exposure and clinical outcomes that the experiment does not resolve.
Different interaction questions also need to remain separate. One concerns whether substances alter each other’s exposure. Another concerns whether their effects combine in a clinically important way. A third concerns whether changing established treatment destabilizes the condition being treated. Finding no clear answer to one of these questions does not settle the others.
A useful clinical discussion therefore starts with a complete medication list, including nonprescription products and investigational substances. The exact product names, the reason each is used and the timing of any new symptoms help a clinician or pharmacist assess the situation. A forum description such as “works on GABA” is too broad to establish compatibility.
Neither the human abstract nor the animal paper provides evidence for independently tapering, replacing or stopping prescribed psychiatric treatment. Those decisions need the prescriber’s involvement. The absence of a documented interaction in these limited sources should be described as an information gap, not as a reassuring negative finding.
The research reviewed here leaves many combinations untested. Its proper use is to identify where a specific clinical question remains unresolved. It is not a stacking guide, and it does not establish that a mixed product shares the safety or effectiveness of either ingredient studied separately.